Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb;29(Suppl):S58-S67.
doi: 10.3350/cmh.2022.0350. Epub 2022 Dec 5.

Comparison between obese and non-obese nonalcoholic fatty liver disease

Affiliations
Review

Comparison between obese and non-obese nonalcoholic fatty liver disease

Wah-Kheong Chan. Clin Mol Hepatol. 2023 Feb.

Abstract

Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of liver conditions that are characterized by excess accumulation of fat in the liver, and is diagnosed after exclusion of significant alcohol intake and other causes of chronic liver disease. In the majority of cases, NAFLD is associated with overnutrition and obesity, although it may be also found in lean or non-obese individuals. It has been estimated that 19.2% of NAFLD patients are lean and 40.8% are non-obese. The proportion of patients with more severe liver disease and the incidence of all-cause mortality, liver-related mortality, and cardiovascular mortality among non-obese and obese NAFLD patients varies across studies and may be confounded by selection bias, underestimation of alcohol intake, and unaccounted weight changes over time. Genetic factors may have a greater effect towards the development of NAFLD in lean or non-obese individuals, but the effect may be less pronounced in the presence of strong environmental factors, such as poor dietary choices and a sedentary lifestyle, as body mass index increases in the obese state. Overall, non-invasive tests, such as the Fibrosis-4 index, NAFLD fibrosis score, and liver stiffness measurement, perform better in lean or non-obese patients compared to obese patients. Lifestyle intervention works in non-obese patients, and less amount of weight loss may be required to achieve similar results compared to obese patients. Pharmacological therapy in non-obese NAFLD patients may require special consideration and a different approach compared to obese patients.

Keywords: Lean; Non-obese; Nonalcoholic fatty liver disease.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

Wah-Kheong Chan has served as a consultant or advisory board member for Roche, Abbvie, Boehringer Ingelheim and Novo Nordisk; and a speaker for Viatris and Hisky Medical.

Figures

Figure 1.
Figure 1.
The effect of genetic, environmental, and confounding factors in the severity of liver disease and outcomes of lean or non-obese patients compared with obese NAFLD patients. Genetic factors may have a more pronounced effect towards the development of NAFLD in lean or non-obese individuals, but the effect may appear less pronounced in the presence of strong environmental factors, such as poor dietary choices and a sedentary lifestyle, in the obese state. Selection bias, underestimation of alcohol intake, and unaccounted weight loss over time from poorly controlled diabetes mellitus and/or loss of muscle mass from advanced liver disease are important confounding factors for varying severity of liver disease and outcomes in lean or non-obese NAFLD patients compared to obese NAFLD patients, although genetic factors may play a role. NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; PNPLA3, patatin-like phospholipase domaincontaining- 3; TM6SF2, transmembrane 6 superfamily member 2. +: Relative frequency of the corresponding variable when comparing between lean or non-obese NAFLD and obese NAFLD.

Comment in

Similar articles

Cited by

References

    1. Wong VW, Chan WK, Chitturi S, Chawla Y, Dan YY, Duseja A, et al. Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-part 1: definition, risk factors and assessment. J Gastroenterol Hepatol. 2018;33:70–85. - PubMed
    1. Kang SH, Lee HW, Yoo JJ, Cho Y, Kim SU, Lee TH, et al. KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2021;27:363–401. - PMC - PubMed
    1. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–1645. - PubMed
    1. Park SH, Plank LD, Suk KT, Park YE, Lee J, Choi JH, et al. Trends in the prevalence of chronic liver disease in the Korean adult population, 1998-2017. Clin Mol Hepatol. 2020;26:209–215. - PMC - PubMed
    1. Le MH, Yeo YH, Li X, Li J, Zou B, Wu Y, et al. 2019 Global NAFLD prevalence: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022;20:2809–2817. e28. - PubMed